The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective

Ang, 2012, Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma, Semin Radiat Oncol, 22, 128, 10.1016/j.semradonc.2011.12.004 Huang, 2017, Overview of the 8th Edition TNM classification for head and neck cancer, Curr Treat Options Oncol, 18, 40, 10.1007/s11864-017-0484-y Mirghani, 2018, Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?, Clin Transl Radiat Oncol, 8, 4, 10.1016/j.ctro.2017.10.005 Chera, 2018, Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, Cancer, 124, 2347, 10.1002/cncr.31338 Chen, 2017, Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study, Lancet Oncol, 18, 803, 10.1016/S1470-2045(17)30246-2 Marur, 2017, E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN cancer research group, J Clin Oncol, 35, 490, 10.1200/JCO.2016.68.3300 Gillison, 2019, Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial, Lancet, 393, 40, 10.1016/S0140-6736(18)32779-X Mehanna, 2019, Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial, Lancet, 393, 51, 10.1016/S0140-6736(18)32752-1 Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med, 354, 567, 10.1056/NEJMoa053422 Bonner, 2010, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, Lancet Oncol, 11, 21, 10.1016/S1470-2045(09)70311-0 Rosenthal, 2016, J Clin Oncol, 34, 1300, 10.1200/JCO.2015.62.5970 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129 Mirghani, 2014, Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status, Eur J Cancer, 50, 1100, 10.1016/j.ejca.2013.12.018 Blanchard, 2011, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site, Radiother Oncol, 100, 33, 10.1016/j.radonc.2011.05.036 Pignon, 2009, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol, 92, 4, 10.1016/j.radonc.2009.04.014 Ang, 2014, Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522, J Clin Oncol, 32, 2940, 10.1200/JCO.2013.53.5633 Dietz, 2018, Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II, Ann Oncol, 29, 2105, 10.1093/annonc/mdy332 Eriksen, 2015, Update of the randomised phase III trial DAHANCA 19: primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck, Radiother Oncol, 114, 10, 10.1016/S0167-8140(15)34769-1 Giralt, 2015, Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial, Lancet Oncol, 16, 221, 10.1016/S1470-2045(14)71200-8 Martins, 2013, Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial, J Clin Oncol, 31, 1415, 10.1200/JCO.2012.46.3299 Mesia, 2015, Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial, Lancet Oncol, 16, 208, 10.1016/S1470-2045(14)71198-2 Bossi, 2016, Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma, Oncotarget, 7, 74362, 10.18632/oncotarget.11413 Guster, 2014, The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines, Radiother Oncol, 113, 345, 10.1016/j.radonc.2014.10.011 Koi, 2017, EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: a preclinical trial in 10 HNSCC-tumour-xenograft models, Radiother Oncol, 124, 496, 10.1016/j.radonc.2017.07.009 Zeng, 2017, Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma, Mol Cancer Ther, 16, 591, 10.1158/1535-7163.MCT-16-0352 Busch, 2016, Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines, Oncotarget, 7, 35832, 10.18632/oncotarget.9028 Ziemann, 2015, Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation +/ Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis, Am J Cancer Res, 5, 1017 Huang, 1999, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck, Cancer Res, 59, 1935 Baumann, 2007, EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms, Radiother Oncol, 83, 238, 10.1016/j.radonc.2007.04.006 Meyn, 2009, Receptor signaling as a regulatory mechanism of DNA repair, Radiother Oncol, 92, 316, 10.1016/j.radonc.2009.06.031 Mukherjee, 2010, Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization, Semin Radiat Oncol, 20, 250, 10.1016/j.semradonc.2010.05.002 Rodemann, 2007, Radiation-induced EGFR-signaling and control of DNA-damage repair, Int J Radiat Biol, 83, 781, 10.1080/09553000701769970 Kriegs, 2016, Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests, Oncotarget, 7, 45122, 10.18632/oncotarget.9161 Stegeman, 2013, EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair, Radiat Res, 180, 414, 10.1667/RR3349.2 Vermorken, 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, 359, 1116, 10.1056/NEJMoa0802656 Srivastava, 2013, Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients, Clin Cancer Res, 19, 1858, 10.1158/1078-0432.CCR-12-2426 Dok, 2014, p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors, Cancer Res, 74, 1739, 10.1158/0008-5472.CAN-13-2479 Rieckmann, 2013, HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity, Radiother Oncol, 107, 242, 10.1016/j.radonc.2013.03.013 Busch, 2017, G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1, Radiother Oncol, 122, 260, 10.1016/j.radonc.2016.11.017